Oncodesign Precision Medicine (FRA:ZR8) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Oncodesign Precision Medicine EBITDA Margin % Related Terms
Oncodesign Precision Medicine EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine EBITDA Margin % Chart
FRA:ZR8 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Oncodesign Precision Medicine's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncodesign Precision Medicine EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Oncodesign Precision Medicine's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine (FRA:ZR8) has a EBITDA Margin % of -3,226.05% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oncodesign Precision Medicine and its competitors. According to the industry distribution chart, Oncodesign Precision Medicine ranks #4 out of 939 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is Oncodesign Precision Medicine's EBITDA Margin % too high?
Oncodesign Precision Medicine's current EBITDA Margin % is -3,226.05%. Based on the distribution chart, Oncodesign Precision Medicine ranks #4 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oncodesign Precision Medicine has a GF Score™ of 32/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncodesign Precision Medicine ranks #4 out of 939 companies for EBITDA Margin %. This places Oncodesign Precision Medicine in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oncodesign Precision Medicine and its competitors. Oncodesign Precision Medicine's current EBITDA Margin % is -3,226.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (FRA:ZR8) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.26, compared to a current price of €0.30 — trading 16.9% above its estimated fair value. The current EBITDA Margin % is -3,226.05%. Oncodesign Precision Medicine's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Oncodesign Precision Medicine (FRA:ZR8), the current EBITDA Margin % is -3,226.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?
Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued.
The current stock price of €0.30 is trading 16.9% above its estimated GF Value™ of €0.26.
GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.
Key valuation signals for FRA:ZR8:
EBITDA Margin %: -3,226.05%
GF Value™: €0.26 vs. price of €0.30 (16.9% above fair value)
No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncodesign Precision Medicine Business Description
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
32GF Score
Get the complete analysis for FRA:ZR8
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZR8 has been successfully added to your 
